Literature DB >> 11581400

Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals.

A Llano1, J Barretina, A Gutiérrez, J Blanco, C Cabrera, B Clotet, J A Esté.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) primary infection is characterized by the use of CCR5 as a coreceptor for viral entry, which is associated with the non-syncytium-inducing (NSI) phenotype in lymphoid cells. Syncytium-inducing (SI) variants of HIV-1 appear in advanced stages of HIV-1 infection and are characterized by the use of CXCR4 as a coreceptor. The emergence of SI variants is accompanied by a rapid decrease in the number of T cells. However, it is unclear why SI variants emerge and what factors trigger the evolution of HIV from R5 to X4 variants. Interleukin-7 (IL-7), a cytokine produced by stromal cells of the thymus and bone marrow and by keratin, is known to play a key role in T-cell development. We evaluated IL-7 levels in plasma of healthy donors and HIV-positive patients and found significantly higher levels in HIV-positive patients. There was a negative correlation between circulating IL-7 levels and CD4(+) T-cell count in HIV-positive patients (r = -0.621; P < 0.001), suggesting that IL-7 may be involved in HIV-induced T-cell depletion and disease progression. IL-7 levels were higher in individuals who harbored SI variants and who had progressed to having CD4 cell counts of lower than 200 cells/microl than in individuals with NSI variants at a similar stage of disease. IL-7 induced T-cell proliferation and up-regulated CXCR4 expression in peripheral blood mononuclear cells in vitro. Taken together, our results suggest a role for IL-7 in the maintenance of T-cell regeneration and depletion by HIV in infected individuals and a possible relationship between IL-7 levels and the emergence of SI variants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11581400      PMCID: PMC114606          DOI: 10.1128/JVI.75.21.10319-10325.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Regulation of T cell proliferation by IL-7.

Authors:  K H Grabstein; A E Namen; K Shanebeck; R F Voice; S G Reed; M B Widmer
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

2.  Cytopathic effect of human immunodeficiency virus in T4 cells is linked to the last stage of virus infection.

Authors:  R Leonard; D Zagury; I Desportes; J Bernard; J F Zagury; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

3.  HIV induces thymus depletion in vivo.

Authors:  M L Bonyhadi; L Rabin; S Salimi; D A Brown; J Kosek; J M McCune; H Kaneshima
Journal:  Nature       Date:  1993-06-24       Impact factor: 49.962

4.  Expression of cytokines and their receptors by human thymocytes and thymic stromal cells.

Authors:  S S Wolf; A Cohen
Journal:  Immunology       Date:  1992-11       Impact factor: 7.397

5.  Predictors of rapid progression to AIDS in HIV-1 seroconverters.

Authors:  I P Keet; P Krijnen; M Koot; J M Lange; F Miedema; J Goudsmit; R A Coutinho
Journal:  AIDS       Date:  1993-01       Impact factor: 4.177

6.  Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

Authors:  M Koot; I P Keet; A H Vos; R E de Goede; M T Roos; R A Coutinho; F Miedema; P T Schellekens; M Tersmette
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

7.  Expression and function of the interleukin 7 receptor in murine lymphocytes.

Authors:  T Sudo; S Nishikawa; N Ohno; N Akiyama; M Tamakoshi; H Yoshida; S Nishikawa
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

8.  Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B.

Authors:  L Osborn; S Kunkel; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

9.  Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse.

Authors:  S K Stanley; J M McCune; H Kaneshima; J S Justement; M Sullivan; E Boone; M Baseler; J Adelsberger; M Bonyhadi; J Orenstein
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

10.  Interleukin 7 is produced by murine and human keratinocytes.

Authors:  C Heufler; G Topar; A Grasseger; U Stanzl; F Koch; N Romani; A E Namen; G Schuler
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

View more
  38 in total

1.  Effects of exogenous IL-2 administration on the homeostasis of CD4+ T lymphocytes.

Authors:  Arnaud Foussat; Laurence Bouchet-Delbos; Jacques Couderc; Dominique Berrebi; Michèle German-Fattal; Marie-Christine Maillot; Ingrid Durand-Gasselin; Pierre Galanaud; James P Di Santo; Dominique Emilie
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

2.  Elevated cytokine and chemokine levels in the placenta are associated with in-utero HIV-1 mother-to-child transmission.

Authors:  Surender B Kumar; Cara E Rice; Danny A Milner; Nilsa C Ramirez; William E Ackerman; Victor Mwapasa; Abigail Norris Turner; Jesse J Kwiek
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

3.  IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

Authors:  Feng-Xiang Wang; Yan Xu; Julie Sullivan; Emily Souder; Elias G Argyris; Edward A Acheampong; Jaime Fisher; Maria Sierra; Michael M Thomson; Rafael Najera; Ian Frank; Joseph Kulkosky; Roger J Pomerantz; Giuseppe Nunnari
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

4.  Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy.

Authors:  Ruy M Ribeiro; Mette D Hazenberg; Alan S Perelson; Miles P Davenport
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  The role of interleukin 7 and its cell receptor in a poor recovery of CD4(+) T cells in HIV-infected patients receiving antiretroviral therapy.

Authors:  E V Saidakova; L B Korolevskaya; N G Shmagel; K V Shmagel; V A Chereshnev
Journal:  Dokl Biol Sci       Date:  2014-11-05

6.  Interleukin-7 enhances memory CD8(+) T-cell recall responses in health but its activity is impaired in human immunodeficiency virus infection.

Authors:  Alison M O'Connor; Angela M Crawley; Jonathan B Angel
Journal:  Immunology       Date:  2010-12       Impact factor: 7.397

7.  Rapid down-regulation of γc on T cells in early SIV infection correlates with impairment of T-cell function.

Authors:  Huanbin Xu; Xiaolei Wang; Bapi Pahar; Xavier Alvarez; Kelsi K Rasmussen; Andrew A Lackner; Ronald S Veazey
Journal:  FASEB J       Date:  2012-02-28       Impact factor: 5.191

8.  Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.

Authors:  Berta Bosch; Julià Blanco; Eduardo Pauls; Imma Clotet-Codina; Mercedes Armand-Ugón; Boyan Grigorov; Delphine Muriaux; Bonaventura Clotet; Jean-Luc Darlix; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

9.  Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.

Authors:  Yves Levy; Christine Lacabaratz; Laurence Weiss; Jean-Paul Viard; Cecile Goujard; Jean-Daniel Lelièvre; François Boué; Jean-Michel Molina; Christine Rouzioux; Véronique Avettand-Fénoêl; Thérèse Croughs; Stéphanie Beq; Rodolphe Thiébaut; Geneviève Chêne; Michel Morre; Jean-François Delfraissy
Journal:  J Clin Invest       Date:  2009-03-16       Impact factor: 14.808

10.  Interleukin 7 reduces the levels of spontaneous apoptosis in CD4+ and CD8+ T cells from HIV-1-infected individuals.

Authors:  Lia Vassena; Michael Proschan; Anthony S Fauci; Paolo Lusso
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.